Attending Doctor at Kidney and Urology Center, Pelvic Floor disorders Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, China
Dr. Hanqi Lei is currently serving as an Attending Physician at the Kidney and Urology Center and the Pelvic Floor Disorders Center, affiliated with The Seventh Affiliated Hospital of Sun Yat-sen University. A medical graduate of Sun Yat-sen University, Dr. Lei has earned high recognition for his clinical and academic prowess. He has expertise in ureteroscopic and laparoscopic techniques and is an active contributor to the field of urologic tumors, calculi, and reconstructive procedures. With over 13 peer-reviewed journal articles, his research continuously bridges medical science with translational application.
👨⚕️ Profile
Scopus
🏆 Suitable for “Best Researcher Award”
Dr. Hanqi Lei is an outstanding candidate for the “Best Researcher Award” owing to his groundbreaking contributions in urological oncology and translational nanomedicine. His extensive publication record in top-tier journals such as Cell Death & Disease, Nano Letters, and Advanced Healthcare Materials highlights both consistency and innovation. With a unique focus on targeting prostate cancer through advanced therapeutic modalities like CRISPR screening, nanoplatforms, and immune modulation, Dr. Lei’s research not only advances academic understanding but also presents clinical relevance, making him an exemplary figure in modern medical research.
🎓 Education
Dr. Lei obtained his MD degree from the prestigious Sun Yat-sen University. His medical journey was marked by rigorous core rotations at the First Affiliated Hospital of Guangzhou Medical University, where he earned honors in Urology. This solid academic foundation set the stage for his specialization in the diagnosis and treatment of complex urological conditions, further enriched by hands-on surgical training.
💼 Experience
With significant clinical exposure and surgical expertise, Dr. Lei currently holds the position of Attending Physician. He manages high patient volumes and is actively involved in surgical procedures and academic mentorship. His experience extends from core clinical care to multidisciplinary research, especially in minimally invasive interventions and cancer treatment innovation. His dual roles in practice and research allow for the rapid translation of lab-based findings to bedside applications.
🔬 Research Interest
Dr. Lei’s research interests lie in the treatment of prostate cancer, focusing on tumors, calculi, and urological reconstruction. His core themes include immune checkpoint therapy, nanomedicine, ferroptosis induction, CRISPR-based screening, and tumor microenvironment modulation. His interdisciplinary approach leverages biomedicine, materials science, and clinical urology to craft precision therapies with enhanced efficacy and minimized side effects.
📚 Publications (Journal Articles and Years)
Dr. Lei has authored multiple high-impact scientific articles. His publications reflect a progression of innovation in prostate cancer therapy using nanotechnology, molecular biology, and immunology. Here is a list of key publications:
-
2021 – Cell Death & Disease: “CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.”
-
2021 – Computational and Structural Biotechnology Journal: “MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer.”
-
2022 – Advanced Healthcare Materials: “Effective sonosensitizer delivery by redox sensitive nanoparticles for prostate cancer sonodynamic therapy.”
-
2023 – Acta Biomaterialia: “Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer.”
-
2024 – Nano Letters: “Acidity-actuated polymer/calcium phosphate hybrid nanomotor for penetrating drug delivery and synergistic anticancer immunotherapy.”
-
2024 – Journal of Controlled Release: “ROS-driven supramolecular nanoparticles for chemo/chemodynamic combination therapy.”
-
2024 – Advanced Healthcare Materials: “Multimodal nanoplatform with ROS amplification to overcome multidrug resistance in prostate cancer.”
-
2025 – Journal of Health, Population and Nutrition: “A cross-sectional study examining the relationship between the advanced lung cancer inflammation index and prostate cancer.”
-
2025 – International Journal of Medical Sciences: “Doublecortin-like kinase 1 promotes stem cell-like properties through the Hippo-YAP pathway in prostate cancer.”
-
2025 – ACS Biomaterials Science & Engineering: “Self-Assembly Oligomeric Anthocyanin-Based Core-Shell Structure of Nanoparticles Enhances the Delivery and Efficacy of Berberine in Osteoarthritis.”